Kornimate/medical-research-clean huggingface dataset:
sleep hygiene education, readiwatchtm actigraphy, and telehealth cognitive behavioral training for insomnia effect, on symptom relief for men with prostate cancer receiving androgen deprivation therapy

Conditions: Prostate Cancer; Sleep Disturbance; Fatigue; Cognitive Impairment

Summary: many treatments for prostate cancer can cause significant fatigue and/or problems with memory and concentration. many treatments for prostate cancer also result in disturbed sleep. improving sleep may reduce feelings of fatigue and improve memory and concentration. the purpose of this study is to test a wearable device that provides real-time feedback on sleep patterns, instruction on how to improve sleep, and a score that indicates periods of time when fatigue and issues with memory and concentration may be most troublesome. the study also is designed to test a type of treatment (cognitive behavioral therapy for insomnia, cbt-i) that is helpful for people who are experiencing disturbed sleep.


Eligibility criteria:
inclusion criteria: * at least 18 years old * diagnosed with any stage of prostate cancer * receiving androgen deprivation therapy * able to speak and read english * score \>/= 8 on insomnia severity index exclusion criteria: * diagnosis of alzheimer's disease or related dementias, or other conditions that would prevent informed consent * sleep apnea not utilizing/or adherent to cpap * uncontrolled restless legs syndrome

Keywords: prostate cancer sleep disturbance fatigue memory concentration
comparison of kohli and foley catheters in suprapubic catheter patients

Conditions: Catheter Infection; Complications; Catheter

Summary: the purpose of this medical research study is to compare two different urinary drainage catheters to see which has fewer problems with blockages and pain. the study involves completing 16 weekly 3-question surveys either online or by phone. the new catheters are fda-approved and will be provided for free. no medications will be given.

the purpose of this study is to see if a redesign of the catheter to remove the extended tip of the conventional urinary catheter will reduce problems with catheter blockage or catheter-associated discomfort. by eliminating the extended tip, the bladder wall will no longer be subject to the tip rubbing on the bladder wall. this could lead to fewer problems with blockages and less irritation and trauma to the bladder lining. a reduction in trauma to the bladder wall could reduce pain, bladder inflammation/irritation and the risk of urinary tract infections.

Eligibility criteria:
inclusion criteria: * indwelling suprapubic foley urinary catheter for at least 30 days prior to entry with anticipation for continued indwelling urinary catheterization for at least 30 days after entry into the study. * catheter associated discomfort or difficulty with mucous plugging of the catheter. exclusion criteria: * inability to provide informed consent * no catheter associated discomfort or problems with mucous plugging

Keywords: suprapubic, urinary catheter
chidamide plus dcag for relapsed/refractory aml

Conditions: AML; Relapse

Summary: despite advances in understanding the complexities of acute myeloid leukaemia (aml), the treatment of refractory or relapsed aml (rraml) remains a daunting clinical challenge.the investigators designed a new regimen, including chidamide, decitabine, aclarubincin, cytarabine and g-csf, to treat rraml.


Eligibility criteria:
inclusion criteria: * men and women whose age more than 18 and less than 59； * patients diagnosed as aml according to the 2008 who (who) myeloid malignant disease diagnosis standard; * patients who relapsed after remission or who can not achieve remission after at least two cycle of systemic therapy (including chemotherapy, hematopoietic stem cell transplantation, etc.); * ecog performance status 0-3; * expected survival time ˃ 3 months; * patients without serious hearts, lung, liver, kidney disease; * patients have not received radiotherapy, chemotherapy, targeted therapy or hematopoietic stem cell transplantation and other treatment within 4 weeks prior to the enrollment; * patients are able to understand and willing to sign informed consent. exclusion criteria: * patients who allergy to the study drug or the drug with similar chemical structure;; * pregnancy, lactation women and women of childbearing age who do not want to practice effective methods of contraception; * active infection; * drug abuse, long-term alcohol abuse so as to affect the results of the evaluation of patients; * patients with mental disorders or other conditions can not obtain informed consent, can not meet the requirements of the study treatment and procedures; * patients have clinical significant qtc interval prolongation history (male \> 450ms. female \>470ms), ventricular heart had tachycardia (vt) and atrial fibrillation (af), ii degree heart block, myocardial infarction attack (mi) within 1 year prior to the enrollment, congestive heart failure (chf), patients of coronary heart disease who have clinical symptoms and need drug treatment. * cardiac ultrasound showed that the diastolic pericardial fluid dark area width ˃ 10mm; * patients have received organ transplantation; * active bleeding * patients have new thrombosis, embolism, cerebral hemorrhage and other diseases or medical history of patients within 1 year prior to enrollment; * the main organs of the surgery is less than 6 weeks; * bone marrow hyperplasia and wbc \<2.0 \* 10\^9/l; * liver function abnormalities (total bilirubin \> 1.5 times of upper limit of normal range , alt / ast \> 2.5 times of the upper limit of normal range or patients with liver involvement whose alt / ast \> 1.5 times of upper limit of normal range), renal anomalies (serum creatinine \> 1.5 times of upper limit of normal value ); * not suitable for the study according to investigator's assessment.

Keywords: demethylating agent chidamide
national longitudinal mortality study (nlms)

Conditions: Cardiovascular Diseases; Heart Diseases

Summary: to estimate probabilities of death by cause for a representative united states population, according to age, sex, race, occupation, industry, income, education, residence, country of birth, calendar year, and a number of other demographic and epidemiologic factors. the representative population is derived from selected bureau of the census files and is matched to the national death index maintained by the national center for health statistics. the bureau of the census provides the data processing, coding and management necessary to complete this objective.

background: the current national longitudinal mortality study began in 1983 with agreements with the census bureau which prepared baseline files from surveys representative of the united states and with the national center for health statistics which prepared the national death index identifying deaths in the baseline populations. the baseline population of over one million persons has been matched to the ndi on several occasions, resulting in approximately 100,000 deaths occurring in 1979 to 1989. using available data, an analysis was conducted relating socio-economic characteristics to subsequent mortality. design narrative: the nlms is a national study of mortality over time among selected census bureau population samples numbering about 2.4 million. the census samples are matched to the national death index (ndi) maintained by the national center for health statistics. the ndi is a file of all u.s. deaths since 1979 and is used to determine which individuals in the current population surveys (cps) have died. the samples are matched every other year to obtain deaths among these cohorts. death certificates are then purchased from the states and coded for causes of death and other data. mortality rates by age, sex, race, national origin, occupation, industry, income, education, state of residence and other factors are then obtained. the follow-up period begins with 1979, the first year covered by the ndi and ends with 1998. the total number of deaths for these cohorts is estimated to be about 250,000. census samples in the nlms are being matched to the centers for medicare \& medicaid services (cms) medicare database. hospitalization, physician, outpatient, and other cms data will be incorporated into the nlms database for all participants meeting the medicare age eligibility criteria. the study continues through december, 2009.

Eligibility criteria:
no eligibility criteria
phewas of a polygenic predictor of thyroid function

Conditions: Thyroid; Genetic Predisposition to Disease

Summary: performing a phenome-wide association study (phewas) identifying clinical diagnoses associated with a polygenic predictor of thyroid stimulating hormone (tsh) levels identified by a previously published genome-wide association study (gwas). phewas will be applied in an electronic-health-record (ehr) cohort including north american (n: 37,154) and european participants using 1,318 phenotypes.

applying a genetic predictor of thyroid stimulating hormone levels to an electronic-health-record cohort to verify associations with thyroid disorders as positive controls, and identify new associations .

Eligibility criteria:
inclusion criteria: * being part of the emerge phase i \& ii network * being part of the biovu resource * falling within 4 standard deviations for each of the first 2 principal components based on common single nucleotide variants (snvs) for the subset of subjects self-identified as "white, non-hispanic" exclusion criteria: * born after 1990
intra-articular magnesium sulfate for tmj dysfunction

Conditions: Temporomandibular Joint Disorders; Temporomandibular Sprain

Summary: mixing the magnesium sulfate with dextrose for management of tmj pain will be studied using intra-articular injection of the solution


Eligibility criteria:
inclusion criteria: * healthy females-no treatment received within the last 6 months-accept treatment protocol exclusion criteria: * unco-operative patients-patients with auto-immune diseases-patients diagnosed with arthritis

Keywords: tmj pain
ruxolitinib managed access program (map) for patients diagnosed with severe/very severe covid-19 illness

Conditions: Severe/Very Severe COVID-19 Illness

Summary: the purpose of this cohort treatment plan is to allow access to ruxolitinib for eligible patients diagnosed with severe/very severe covid-19 illness. the patient's treating physician should follow the suggested treatment guidelines and comply with all local health authority regulations. the requesting treating physician submitted a request for access to drug (often referred to as compassionate use) to novartis which was reviewed and approved by the medical team experienced with the drug and indication. please refer to the latest investigator's brochure (ib) or approved label for overview of ruxolitinib including: non-clinical and clinical experience, risk and benefits. novartis will continue to provide any new safety information to the treating physician as they emerge.


Eligibility criteria:
inclusion criteria: patients eligible for inclusion in this treatment plan have to meet all of the following criteria: written patient informed consent or assent must be obtained prior to start of treatment. * patients aged ≥ 6 years * patients clinically diagnosed with sars-cov-2 infection, either through positive serum antibodies (igm or igg); or by pcr; or by other approved diagnostic methodology. patients with presumptive diagnosis of covid-19 (other respiratory causes ruled out and sars-cov-2 test pending) may be included. * adult and adolescent patients (≥12years), who meet one of the below criteria * respiratory frequency ≥ 30/min * oxygen saturation ≤ 93% on room air (fio2=0.21) * arterial oxygen partial pressure (pao2)/ fraction of inspired oxygen (fio2) \<300mmhg(1mmhg=0.133kpa) (corrective formulation should be used for higher altitude regions (over 1000m). and -- patients with lung imaging showing pulmonary infiltrates (chest x-ray or ct scan) pediatric patients (≥6-\<12 years) who meet one of the below criteria (where appropriate): * shortness of breath * oxygen saturation \<92% on room air (fi)2=0.21) * labored breathing (e.g. wheezing, flaring of nostrils, three concave sign), cyanosis, intermittent apnea. * lethargy or convulsions * refusal to eat or difficulty with feeding; signs of dehydration exclusion criteria: * patients eligible for this treatment plan must not meet any of the following criteria: * history of hypersensitivity to any drugs or metabolites of similar chemical classes as ruxolitinib * presence of severely impaired renal function defined by serum creatinine \> 2 mg/dl (\>176.8 μmol/l), or have estimated creatinine clearance \< 30 ml/min measured or calculated by cockroft gault equation or calculated by the updated bedside schwartz equation. * pregnant or nursing (lactating) women. * patients who are not able to understand and to comply with treatment instructions and requirements unless health care proxy is able to provide consent.

Keywords: corona virus pneumonia virus covid-19 covid
the effect of music listened by patients with moderate dental anxiety during the restoration of occlusal caries

Conditions: Dental Anxiety; Music; Physical Stress

Summary: it is aimed to evaluate the effect of music listened by patients with moderate dental anxiety during the restoration of posterior occlusal dental caries on vital signs of the participants.

the study will be applied on 70 patients; 35 patients will be in the control group (the group not listening to music during treatment), 35 patients will be in the experimental group (the group listening to music during treatment). modified dental anxiety scale consisting of 5 questions will be applied to the participants who come to the clinic and have occlusal dental caries in the posterior region. the participants whose scores are between 10-18 according to this scale will be included in the study. one occlusal tooth decay will be treated. before starting treatment, saliva cortisol levels, heart rate, body temperature, systolic and diastolic blood pressure and oxygen saturation measurements will be made. the participants will be asked to spit in sterile plastic containers for saliva cortisol measurement. during dental treatment, the participants will listen to music in experimental group. in control group the participant will not listen to music. heart rate, body temperature, systolic and diastolic blood pressure and oxygen saturation measurements will be repeated in the middle of the treatment (without going through the restoration phase when the cavity is opened). saliva cortisol levels, heart rate, body temperature, systolic and diastolic blood pressure and oxygen saturation measurements will be repeated when the treatment is completed. the questionnaire containing the modified dental anxiety scale will be re-administered to the participants.

Eligibility criteria:
inclusion criteria: must be healthy volunteers, clinical diagnosis of at least one occlusal dental caries, must have moderate dental anxiety - exclusion criteria:unhealthy volunteers, teeth with dental cavities in the adjacent teeth where the rubber dam would not be placed, and dental caries closer than 1 mm to the pulp tissue were not included in the study

Keywords: dental anxiety music
assess safety, tolerability and pk of azd3199 in japanese

Conditions: Healthy

Summary: the primary objective of the study is to investigate the safety and tolerability of single and multiple once daily ascending doses of azd3199 delivered as dry powder via the turbuhaler inhaler in healthy male japanese subjects by assessment of incidence and nature of adverse events (aes), clinically significant abnormalities in ecg parameters, blood pressure (bp), pulse rate, lung function parameters, body temperature and laboratory variables (clinical chemistry, haematology and urinalysis). the secondary objectives of the study are to investigate the pharmacokinetics (pk) of single and multiple ascending doses of azd3199 by assessment of the degree of accumulation, dose proportionality and time linearity in healthy japanese subjects, and to investigate systemic β 2- adrenoreceptor mediated effects of single and multiple ascending doses of azd3199 by assessment of potassium and lactate concentrations, tremor and palpitations, heart rate, qtc, pulse rate, blood pressure and fev1.


Eligibility criteria:
inclusion criteria: * be healthy japanese volunteers, both of the volunteer's parents, and all grandparents must be japanese. the volunteer must have been born in japan, have a valid japanese passport and must not have lived outside japan for for more than 5 years. * bmi 18 - 27, weight 50 - 85 kg * be non-smoker or ex-smoker who has stopped smoking (or using other nicotine products) for \>6 months prior to study start. * clinical normal physical findings exclusion criteria: * any clinically significant disease or disorder * any clinically relevant abnormal findings in physical examination, clinical chemistry, haematology, urinalysis, vital signs, ecg or lung function at baseline * any clinically important abnormalities in rhythm, conduction or morphology of resting ecg that may interfere with the interpretation of qtc interval changes. * use of any medication (including otc), herbal preparations, vitamins or nutritional supplements within 2 weeks prior to visit 2, except for occasional intake of paracetamol (maximum daily dose of 4 g)

Keywords: azd3199 japanese healthy volunteers phase i study single and multiple ascending dose safety tolerability pk
study of dysarthria, and the appearance of non-dopaminergic signs in idiopathic parkinson's disease

Conditions: Parkinson Disease

Summary: pilot study: * longitudinal follow up of the prody-gi cohort for parkinson's disease (pd) * observational study of upper and lower axial symptoms' occurence in 30 pd patients in on and off drug conditions, 30 aged matched control subjects and 10 control subjects with supra nuclear palsy * multi modal approach: functional mri, clinical , ent assessment, respiratory assessment, neuropsychological and gait evaluations

prospective, clinical assessment of : * cognition and diadochokinetic task during fmri in 30 pd patients (in off and on condition) * motor assessment using vicon gait and balance analysis * pulmonary functional testing in off and on drug condition * quality of life * clinical neurological mds updrs , n fog questionnaire * ent and speech therapist evaluation in off and on drug condition

Eligibility criteria:
inclusion criteria: parkinson's disease group : patients with parkinson's disease, who where included in the prodygi-1 cohort still meeting the mp criteria, always followed in the service of neurology and pathology of the movement. pathological control group: * patients suffering from richardson syndrome. * aged over 18 healthy control group: * age-matched (± 5 years) * recruited on the basis of volunteering. * free from any progressive neurological pathology after clinical examination and moca. exclusion criteria: for all groups: * pregnant or lactating woman * extra-neurological severe respiratory pathology * terminal heart failure * contraindication to mri * refusal / withdrawal / inability to give consent * ent pathology.

Keywords: levodopa axial symptoms
temporomandibular joint and soft tissue mobilisation techniques on bening paroxymal vertigo

Conditions: Soft Tissue Mobilisation; Vestibular Exercises; Physiotherapy; Vertigo, Paroxysmal; Temporomandibular Joint Disorders

Summary: the purpose of this study was to investigated effectiveness of temporamandibular joint and soft tissue mobilization on patients with benign paroxysmal positional vertigo (bppv).

aim: in this study was aimed to investigated effectiveness of temporamandibular joint and soft tissue mobilization on patients with benign paroxysmal positional vertigo (bppv). material and methods; dix hallpike maneuver was administered to all patients to confirm the diagnosis at the initial evaluation. if the dix hallpike test was positive, epley maneuver was applied the patients were randomly divided into 2 groups as study group (n=) and control groups (n= ). temporomandibular joint ve soft tissue techniques were applied 30 minutes once a week for 4 weeks by physiotherapist. routin medication therapy was applied to control group. both groups were asked to do the home exercise program twice a day consisting of vestibular exercise videos sent over whatss app. it was questioned with a phone call once a week whether the exercises were done or not. patients were evaluated by dizziness disability inventory (dhi) , dizziness assessment- visual analogue scale (vas), vertigo symptom scale-short form (vss) , beck anxiety inventory (bai) , vertigo dizziness imbalance questionnaire (vdi) , tinnitus disability scale (tds), romberg posture test , tandem posture test, semitandem tandem balance test, fonseca's anamnestic index (fai) and amount of mouth opening was measured with goniometer before and after treatment.

Eligibility criteria:
inclusion criteria: * being diagnosed with positional vertigo, * being between the ages of 18-65 * dix halpike maneuver test (+), * those who volunteered to participate in the study * able to read and write. exclusion criteria: * findings of acute or chronic infection at the end of ent examination, * considered to have a neurological pathology that causes dizziness, * head trauma, history of surgical operation, * having lower extremity pain that prevents standing and weight bearing, * having a history or symptoms of vestibular system diseases other than bppv, * presence of sudden sensory hearing loss and chronic otitis media, * pregnancy, * the presence of serious cognitive impairment detected by the physician at a level that prevents the tests from being performed, * not having the mental level to understand and answer the survey questions, * cervical pathologies that may cause dizziness.

Keywords: bening paroxymal positional vertigo temporomandibular joint mobilization soft tissue mobilisation vestibular exrecises physiotherapy otorhynology
long-term safety, tolerability and efficacy of aclidinium bromide in patients with moderate to severe chronic obstructive pulmonary disease (copd) (las-md-35)

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the purpose of this study is to evaluate the safety, tolerability and efficacy of inhaled aclidinium bromide at two dose levels in patients with moderate to severe, stable chronic obstructive pulmonary disease. the study will be 56 weeks in duration; a 2-week rin-in period, a 52-week treatment period and a 2-week follow up phone call. all patients will be randomized to one of two doses of aclidinium bromide.


Eligibility criteria:
inclusion criteria: * a diagnosis of stable moderate to severe copd as defined by the global initiative for chronic obstructive lung disease (gold) guidelines, 2010; postbronchodilator fev1/fvc \< 70%, and postbronchodilator fev1 ≥ 30% and \< 80% predicted * current or former cigarette smokers exclusion criteria: * patients who have been hospitalized for an acute copd exacerbation within 3 months before the first visit * respiratory tract infection or copd exacerbation in the 6 weeks before visit 1 * patient with any clinically significant respiratory conditions other than copd, cardiovascular conditions or mental illness * history or presence of asthma verified from medical records * chronic use of oxygen therapy greater than or equal to 15 hours per day * patient with uncontrolled infection due to hiv and/or active hepatitis * patients with a history of hypersensitivity reaction to inhaled anticholinergics * patients with clinically significant cardiovascular conditions, including myocardial infarction during the previous 6 months, newly diagnosed arrhythmia within the previous 3 months, unstable angina, unstable arrhythmia that had required changes in pharmacological therapy or other intervention.

Keywords: chronic obstructive pulmonary disease copd chronic bronchitis emphysema airflow obstruction, chronic chronic airflow obstruction chronic obstructive airway disease chronic obstructive lung disease